Article Figures & Data
Figures
- Abstract B02 Figure 1
Comparison of M-F 8am–5pm mean sedentary time: baseline to 12-week
- Abstract B02 Figure 2
Comparison of femoral FMD %: baseline to 12-week
- Abstract B03 Figure 1
Cardiac MR with diffuse mass extending into interventricular septum involving both ventricles with encasement of coronary arteries
- Abstract A31 Figure 1
- Abstract A34 Figure 1
- Abstract B61 Figure 1
Electrocardiagram showing sinus bradycardia with inferior ST-segment elevation in leads II, III, aVF and anterior ST-segment depression in leads V1–4
- Abstract B61 Figure 2
Coronary angiogram show 99% occlusion of dominant mid-left circumflex artery
- Abstract B61 Figure 3
CT abdomen with contrast showing gas in the gallbladder well and lumen representing emphysematous cholecystitis with moderate pneumobilia
- Abstract B61 Figure 4
CT abdomen with contrast showing 1 to 2 intrahepatic gas containing foci likely representing abscess formation
- Abstract C29 Figure 1
Electrocardiogram with inferolateral ST-segment elevation myocardial infarction
- Abstract C29 Figure 2
Echocardiogram in end systole with left ventricular akinesis. White arrow indicating LV apical thrombus. (LV: left ventricle, RV: right ventricle)
- Abstract C29 Figure 3
Brain MR with area of T2/FLAIR hyperintensity
- Abstract A16 Figure 2
- Abstract A16 Figure 3
- Abstract A06 Figure 1
- Abstract A06 Figure 2
- Abstract A06 Figure 3
- Abstract A06 Figure 4
- Abstract A06 Figure 5
- Abstract A62 Figure 1
- Abstract B33 Figure 2
- Abstract B33 Figure 3
- Abstract A37 Figure 1
- Abstract A37 Figure 2
- Abstract A37 Figure 3
- Abstract B62 Figure 1
- Abstract C01 Figure 1
- Abstract A22 Figure 2
Is the gene correlation map of 171 genes enriched in the stroma of pancreatic adenocarcinoma. These genes indude those associated with cytolytic activities, desmoplastic reaction, stromal and immune cells, and genes associated with simulatory or inhibitory signals of antigen presenting cells and Tcells. Each box demonstrates a squared correlation coefficient (R2) of two respective genes
- Abstract A54 Figure 1
Laryndoscopy showing paralysis of left vocal cord
- Abstract C05 Figure 1
Cardiac MRI displaying masses within LV apical septum (1), left lateral wall (2), and inferolateral wall (3). LV: Left Ventricle
- Abstract C05 Figure 2
CT scan of chest with large necrotic mass in right lung apex
- Abstract C53 Figure 1
Peripheral blood smear with multiply infected RBC’s with plasmodium falciparum
- Abstract A12 Figure 1
(A) miMCD cell extracts; (B) HRCTE cell extracts; (C) rat urine; (D) patient urine
- Abstract A12 Figure 2
- Abstract A12 Figure 3
- Abstract A12 Figure 4
- Abstract A23 Figure 1
tFGF23 levels with iron sucrose treatment
- Abstract A23 Figure 2
iFGF23 levels with iron sucrose treatment
- Abstract C39 Figure 1
- Abstract B28 Figure 1
- Abstract A02 Figure 1
- Abstract B31 Figure 1
- Abstract B31 Figure 2
- Abstract B31 Figure 3
Tables
- Abstract C16 Table 1
Demographics, comorbidities, and clinical data according to factors of admission
Overall (n=109) A (n=15) B (n=19) C (n=22) D (n=5) E (n=33) F (n=15) Age (years) 56±13 54±9 53±13 52±12 59±20 59±14 66±12 Sex (% Male) 68 73 79 59 80 60 73 Hispanic (%) 63 73 79 68 60 51 53 Non-Hispanic White (%) 21 20 15.79 4.55 20 27.27 40 DM (%) 51 53.3 57.9 40.9 25 57.6 53.3 HTN (%) 70 80 84.2 59.1 25 72.7 66.7 CVA (%) 14 20 10.5 9.1 0 15.2 20 PVD (%) 9 20 15.8 4.6 0 6.1 13.1 Current Smoker (%) 28 33.3 15.8 36.4 20 21.2 40 SBP (mmHg) 134±27 145±32 128±28 144±26 113±10 127±23 137±19 DBP (mmHg) 82±20 91±25 81±21 91±22 76±18 76±16 77±14 EF (%) 31±18 26±17 33±21 27±15 30±19 36±17 37±22 PASP (mmHg) 45±12 40±10 43±9.51 45±11 58±10 48±15 46±12 DM=diabetes mellitus, HTN=hypertension, CVA=cerebral vascular accident, PVD=peripheral vascular disease, SBP=systolic blood pressure, DBP=diastolic blood pressure, EF=ejection fraction, PASP=pulmonary artery systolic pressure
- Abstract A23 Table 1
Characteristics before and after iron sucrose infusion
N=22 Pre-iron sucrose Post-iron sucrose Age, yrs 56±13.4 - Female, % 73 - Ferritin (ng/mL) 47 (30, 74) 252 (205, 386) Transferrin Saturation (%) 19±6 25±6 Hemoglobin (g/dL) 10.5±1.0 11.0±1.2 eGFR ml/min/1.73m2 32.8±18.4 31.9±17.8 Phosphorus (mg/dL) 3.7±0.7 3.6±0.9 tFGF23 (Ru/ml) 367 (164, 535) 176 (92, 566) iFGF23 (pg/ml) 162 (81, 473) 134 (97, 536) - Abstract A46 Table 1
Clinical characteristics by outcome
All (n=80) Failure (n=24) Success (n=56) p-value Diabetes, % 61.2 50.0 66.1 0.2 Aspirin, % 56.2 33.3 66.1 0.007 Indication for procedure, % 55.0 33.3 64.3 0.01 Multiple stenoses, % 42.5 41.7 42.9 0.4 Cephalic arch stenosis, % 17.5 12.5 19.6 0.4 Pre-PTA stenosis 59.6 (17.1) 60.8 (18.9) 59.1 (16.3) 0.6 POst-PTA stenosis 19.8 (14.2) 16.9 (12.3) 21.0 (14.8) 0.15 Change in stenosis after PTA 39.8 (19.1) 43.9 (20.5) 38.1 (18.3) 0.13 - Abstract B24 Table 1
Demographics
Age range 30–96 Mean Age 67 Gender Distribution Male – 21
Female – 17 - Abstract B24 Table 2
Comparison of drug treatment
Vancomycin group (n=18) Cefazolin group (n=20) Repeat 3 3 Recurrent - 1 Relapse 2 - - Abstract B24 Table 3
In vs out patient
In (n=22) Out (n=16) Repeat 4 2 Recurrent 1 - Relapse 1 1 - Abstract B24 Table 4
Vancomycin treatment in vs out patient
Vancomycin in (n=15) Vancomycin out (n=3) Repeat 2 1 Recurrent - - Relapse 1 1 - Abstract B24 Table 5
Cefazolin treatment in vs out patient
Cefazolin in (n=7) Cefazolin out (n=13) Repeat 2 1 Recurrent 1 - Relapse - -
- Article
- Midwestern Regional Meeting, Thursday, April 26–27, 2018, Chicago, IL, Cardiology/Cardiovascular Disease
- Diagnosis or Treatment of a Disease Process or Clinical Syndromes
- Endocrinology/Metabolism
- Epidemiology/Health Outcomes/Quality Improvement/Bio-Informatics
- Gastroenterology/Clinical Nutrition
- Hematology and Oncology
- Infectious Disease
- Nephrology
- Neurology/Neurodegeneration
- Pathophysiology
- Pulmonary/Critical Care
- Rheumatology/Immunology/Allergy
- Figures & Data
- eLetters
- Info & Metrics